DWP450 for Treating Moderate to Severe Glabellar Lines (NCT06354127) | Clinical Trial Compass
CompletedPhase 3
DWP450 for Treating Moderate to Severe Glabellar Lines
China473 participantsStarted 2020-08-12
Plain-language summary
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
Who can participate
Age range20 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult males or females aged 20-65 years old.
* Moderate to severe (grade 2-3) glabellar lines based on investigator's assessment of severity of glabellar lines at maximum frown.
Exclusion Criteria:
* Having received any glabellar (including forehead) cosmetic procedures/surgeries, such as dermal filling, face lifting, photoelectric therapy, hydro lifting, microneedle, chemical peeling or scar removal surgery, or dermabrasion within 6 months prior to screening.
* Planning to receive any facial cosmetic procedures/surgeries, including but not limited dermal filling, face lifting, photoelectric therapy, hydro lifting, microneedle, chemical peeling or scar removal surgery, during the study period.
* Skin infection at injection site or systemic skin disease assessed with the potential to interfere with efficacy evaluation or safety evaluation of glabellar lines or forehead lines.
* Glabellar lines that cannot be fully flattened through surgery, by hand or by other methods.
What they're measuring
1
Response rate based on the investigator's on-site assessment of severity of glabellar lines at maximum frown